EU lays out pros and cons to on­shoring more API pro­duc­tion

As the US em­barks on a bil­lion-dol­lar ini­tia­tive to on­shore ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) man­u­fac­tur­ing, the Eu­ro­pean Union re­leased a re­port ear­li­er this month weigh­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER